Cohance Lifesciences Key Ratios
NSE: COHANCE | BSE: 543064
₹456.40
As on 18-Nov-2026IST
Market cap
₹17,462 Cr
Revenue (TTM)
₹2,063 Cr
P/E Ratio
368.6
P/B Ratio
4.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 12.88 | -14.21 | -21.32 | 16.58 | 13.42 |
| EBIT | 69.43 | -119.23 | -93.62 | -60.64 | -40.33 |
| Net Profit | 163.10 | -79.45 | -83.60 | -46.01 | -29.80 |
| EPS | 163.10 | -79.45 | -91.13 | -58.21 | -39.81 |
| Book Value | -- | -- | -27.37 | 14.29 | 17.01 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 22.71 | 29.70 | 1.58 | 10.56 | 24.16 |
| Net Margin
| 17.19 | 22.67 | -0.27 | 6.52 | 18.08 |
| Return on equity
| 12.38 | 19.17 | 1.74 | 4.02 | 17.25 |
| Return on Capital
| 16.71 | 25.89 | -- | 6.12 | 22.80 |
| Return on Assets
| 9.65 | 14.95 | -0.10 | 2.68 | 12.52 |
| Debt to Equity (x)
| -- | -- | 0.01 | 0.04 | 0.07 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
6.12
|
22.80
|
21.22
|
33.41
|
|
Peer Median
|
--
|
14.77
|
14.72
|
18.85
|
--
|
ROE
1.74
Lower than Peers by 9.02
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
1.74
|
4.02
|
17.25
|
15.87
|
25.21
|
|
Peer Median
|
10.76
|
12.35
|
11.67
|
14.92
|
--
|
ROA
-0.10
Lower than Peers by 6.82
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-0.10
|
2.68
|
12.52
|
13.76
|
20.18
|
|
Peer Median
|
6.72
|
6.87
|
7.86
|
9.06
|
--
|
EBIT Margin
1.58
Lower than Peers by 11.17
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
1.58
|
10.56
|
24.16
|
33.41
|
39.26
|
|
Peer Median
|
12.75
|
13.55
|
15.03
|
14.71
|
--
|
Net Margin
-0.27
Lower than Peers by 9.33
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-0.27
|
6.52
|
18.08
|
26.97
|
29.66
|
|
Peer Median
|
9.06
|
8.30
|
9.33
|
8.49
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
14.88
|
24.96
|
33.75
|
34.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-21.32
Lower than Peers by 30.18
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-21.32
|
-13.03
|
148.11
|
-21.56
|
1.52
|
|
Peer Median
|
8.85
|
17.50
|
10.27
|
11.85
|
--
|
EBIT Growth
-93.62
Lower than Peers by 110.87
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-93.62
|
-61.97
|
79.45
|
-33.25
|
-3.03
|
|
Peer Median
|
17.24
|
24.88
|
24.15
|
28.00
|
--
|
Net Profit Growth
-83.60
Lower than Peers by 100.85
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-83.60
|
-69.00
|
61.26
|
-26.99
|
-9.37
|
|
Peer Median
|
17.25
|
36.93
|
30.29
|
36.51
|
--
|
EPS Growth
-91.13
Lower than Peers by 101.00
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
-91.13
|
-75.53
|
62.30
|
-27.00
|
-9.37
|
|
Peer Median
|
9.87
|
26.79
|
24.50
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
9.14
|
74.11
|
18.07
|
13.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.01
Lower than Peers by 0.03
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
0.01
|
0.04
|
0.07
|
0.02
|
0.04
|
|
Peer Median
|
0.04
|
0.24
|
0.23
|
0.20
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
0.02
|
0.02
|
0.02
|
0.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.98
Higher than Peers by 0.22
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
1.98
|
2.78
|
2.49
|
10.67
|
3.81
|
|
Peer Median
|
1.76
|
1.83
|
1.79
|
1.96
|
--
|
Quick Ratio
1.14
Lower than Peers by 0.06
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
1.14
|
1.91
|
1.83
|
8.71
|
2.78
|
|
Peer Median
|
1.20
|
1.19
|
1.47
|
1.44
|
--
|
Interest Coverage
1.21
Lower than Peers by 6.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
1.21
|
6.56
|
16.65
|
55.45
|
44.69
|
|
Peer Median
|
8.12
|
7.74
|
9.42
|
8.58
|
--
|
Operating Efficiency
Debtors to sales
22.74
Lower than Peers by 2.56
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
22.74
|
30.02
|
29.60
|
12.71
|
8.28
|
|
Peer Median
|
25.30
|
23.05
|
25.82
|
26.12
|
--
|
Asset Turnover
0.37
Lower than Peers by 0.30
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
0.37
|
0.40
|
0.67
|
0.48
|
0.66
|
|
Peer Median
|
0.66
|
0.79
|
0.75
|
0.77
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
116.90
|
63.37
|
42.46
|
47.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
82.83
|
48.87
|
94.43
|
81.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
153.58
|
69.70
|
65.80
|
79.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
46.15
|
42.55
|
71.09
|
48.66
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
368.62
Higher than Peers by 325.15
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
368.62
|
64.45
|
60.59
|
57.37
|
29.26
|
|
Peer Median
|
43.48
|
43.48
|
39.70
|
33.48
|
--
|
Price / Book Value
4.46
Higher than Peers by 0.56
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
4.46
|
2.97
|
8.28
|
8.41
|
6.93
|
|
Peer Median
|
3.91
|
4.07
|
3.72
|
4.21
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
--
|
--
|
--
|
--
|
1.27
|
|
Peer Median
|
0.19
|
0.09
|
0.16
|
0.21
|
--
|
EV/EBITDA
67.74
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
67.74
|
25.29
|
34.27
|
36.80
|
19.39
|
|
Peer Median
|
--
|
32.90
|
30.23
|
29.90
|
--
|
Market Cap
17,462
Higher than Peers by 8,289
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
|
17,462
|
11,551
|
29,528
|
17,226
|
12,033
|
|
Peer Median
|
9,173
|
4,938
|
4,851
|
2,099
|
--
|